Christopher Perry, PhD discusses how his laboratory aims to discover mechanisms by which metabolic dysfunction causes muscle weakness and apply these findings to develop new therapies for muscle disorders. Homira Osman, PhD provides a particular focus on leveraging scientific findings for practice and policy and linking trainees with patient communities.
Experts present key considerations in the design of rigorous preclinical studies in rodent models of muscular dystrophy, including animal model selection, assays and endpoints, and how your results can inform translation to the clinic.
Suzie Buono discusses the work she and her team have done to provide an example of treating a dominant disease by targeting both alleles, suggesting that this strategy may be applied to other dominant diseases.
Jordan Fuqua discusses how autophagy and proteolytic processes are regulated in skeletal muscle, specifically looking at ULK1 and ULK2 and their roles in maintaining skeletal muscle homeostasis, morphology, protein aggregate degradation and autophagy.
Charles Meshul, Carolanne Milligan, and Tom Hampton discuss methodology, best practices, and techniques for identifying early and subtle quantitative physiological markers of strength, balance, and coordination in animal models of pain, CNS, neuromuscular, and neurodegenerative disorders.